Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Plain-language summary

This study evaluates the safety, tolerability and effects in the body of oral EP262 compared with placebo in people with atopic dermatitis. Patients with an active atopic dermatitis diagnosis for at least 1 year took part. The study was conducted in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Escient Pharmaceuticals, Inc

Intervention

Oral EP262, Placebo

Start date

10/25/2023

Estimated completion

7/31/2024

Countries

United States, Canada

Related genes

Locations

• Birmingham, United States
• Miami Lakes, United States
• Plainfield, United States
• Rockville, United States
• Troy, United States
• Boardman, United States
• College Station, United States
• South Jordan, United States
• Spokane, United States
• Montreal, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year
* BSA of 3% to 20% and a vIGA-AD score of ≥3

Exclusion Criteria:

* Other active skin diseases associated with chronic pruritus
* Clinically infected atopic dermatitis that requires antibiotic therapy
* Use of specific treatments for atopic dermatitis